Why the study?
Does VASP-guided clopidogrel maintenance therapy reduce MACCE in atrial fibrillation patients requiring anticoagulation and scheduled for PCI?
Does VASP-guided clopidogrel maintenance therapy reduce MACCE in atrial fibrillation patients requiring anticoagulation and scheduled for PCI?
VASP-guided clopidogrel dosing reduces MACCE but increases minor bleeding compared to fixed-dose clopidogrel in AF patients undergoing PCI who require anticoagulation.
Answers are grounded in this paper and cite their sources.
VASP-guided clopidogrel was associated with lower MACCE; leaves open need for randomized confirmation before practice change.
BACKGROUND: In a previous study, we found that titrating clopidogrel maintenance doses (MDs) according to vasodilator-stimulated phosphoprotein (VASP) monitoring minimised the rate of major adverse cardiovascular and cerebral events (MACCE) after percutaneous coronary intervention (PCI) without increasing bleeding in patients with high on-treatment platelet reaction to clopidogrel. This study aimed to investigate whether VASP-guided clopidogrel MD could reduce thromboembolism and bleeding in atrial fibrillation (AF) patients requiring anticoagulation and scheduled for PCI. METHODS: AF patients scheduled for PCI were recruited between July 2014 and July 2016. These patients were allocated into VASP-guided (n = 250) and control (n = 253) groups depending on the clopidogrel MD profile. In the VASP-guided group, clopidogrel MD was titrated by the platelet reactivity index (PRI), whereas in the control group, clopidogrel MD was fixed at 75 mg per day. The primary endpoint was MACCE and secondary endpoints were thrombolysis in myocardial infarction (TIMI) major and minor bleeding 1 year after PCI. MACCE was less in the VASP-guided group than in the control group (2.5% vs. 5.0%, P = 0.02). The incidence of major bleeding was comparable between both groups (3.0% vs. 2.8%, P = 0.72) and minor bleeding was higher in the VASP-guided group than in the control group (15.3% vs. 9.7%, P = 0.03). Kaplan-Meier analysis indicated that there was no difference in survival between both groups (log-rank test, P = 0.68). CONCLUSIONS: In AF patients requiring anticoagulation and scheduled for PCI, VASP-guided antiplatelet therapy reduced major cardiovascular and cerebral adverse events, accompanied by increased minor bleeding events. TRIAL REGISTRATION: The present study was retrospectively registered in the Chinese Clinical Trial Registry, A Primary Registry of the International Clinical Trial Registry Platform, World Health Organisation (Registration no: ChiCTR-IOR-17013854 ). The registered date was December 11, 2117.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: